Cereno Scientific Secures SEK 665 Million Financing to Advance Rare Disease Pipeline Through 2027
Key Insights
Cereno Scientific (search) secured SEK 665 million in total financing through a combination of SEK 350 million in loans and SEK 100 million in directed share issue, with additional potential proceeds from warrant exercises.
The funding will primarily support the global Phase IIb trial of CS1, an HDAC (search) inhibitor for pulmonary arterial hypertension (search) that has shown positive Phase IIa results and received FDA Fast Track designation.
The company's pipeline includes three disease-modifying drug candidates targeting rare cardiovascular and pulmonary diseases, with CS014 advancing to Phase II for idiopathic pulmonary fibrosis (search) and CS585 in preclinical development.
Cereno Scientific (search) announced a comprehensive financing package totaling SEK 665 million upon full exercise of warrants and convertibles, providing the Swedish biotech with financial runway through Q4 2027 to advance its pipeline of rare disease treatments. The financing combines a SEK 350 million loan facility with a SEK 100 million directed share issue, positioning the company to execute critical Phase IIb and Phase II trials.
The financing agreement with Fenja Capital II A/S (search) and an associated company includes SEK 175 million in convertible loans and a SEK 175 million loan facility. Fenja Capital holds approximately 71.4% of the financing arrangement, with the associated company providing the remaining 28.6%. The directed share issue was subscribed by existing shareholders and external investors at SEK 7 per share, representing a 2% premium to the volume-weighted average price over the last ten trading days.
Lead Program Advances Toward Global Phase IIb Trial
The primary focus of the financing centers on CS1, Cereno's lead HDAC (search) inhibitor targeting pulmonary arterial hypertension (search) (PAH). The compound has demonstrated positive Phase IIa results showing a favorable safety and tolerability profile alongside efficacy signals indicating disease modification. Notably, CS1 showed encouraging signals of reverse vascular remodeling and improvement of right heart function in the Phase IIa trial.
The FDA has endorsed the Phase IIb study design through a Type C meeting and granted Fast Track designation to CS1, clearing the path for a global, multi-center, placebo-controlled Phase IIb trial. An Expanded Access Program currently enables patients who completed the Phase IIa trial to continue accessing CS1.
"This financing arrangement provides the resources required to execute the planned Phase IIb trial of CS1 in PAH," said Sten R. Sörensen, CEO and Board member of Cereno Scientific (search). "It also enables us to continue progressing our broader pipeline toward key clinical and regulatory milestones while maintaining the financial and strategic flexibility necessary at this stage of development."
Expanding Pipeline Shows Promise Across Rare Diseases
Beyond CS1, Cereno's pipeline includes CS014, a second HDAC (search) inhibitor that completed a Phase I first-in-human study demonstrating favorable safety and tolerability at exposure levels predicted to support disease-modifying effects. These results support progression into Phase II trials for idiopathic pulmonary fibrosis (search) (IPF), addressing another area of high unmet medical need.
The company's third program, CS585, represents a selective prostacyclin (IP) receptor agonist advancing through preclinical development in collaboration with the University of Michigan. Preclinical data suggests CS585 could potentially address thrombosis prevention without increased bleeding risk and pulmonary hypertension, with rare thrombotic diseases under evaluation as potential indications.
Strategic Financing Structure Provides Operational Flexibility
The financing agreement includes several components designed to provide both immediate funding and future flexibility. The convertible loans carry a conversion price of SEK 10.00 and may be converted into B-shares by lenders up to five million shares per quarter through Q1 2027. Additionally, 9.6 million warrants issued to lenders carry a subscription price of SEK 12.00 per share and remain exercisable until November 2030.
The directed share issue includes 10 million warrants of series 2025/26:1 issued free of charge, exercisable from October 1, 2026, through December 31, 2026, at SEK 10.00 per share. Upon full exercise, these warrants would provide an additional SEK 100 million in proceeds.
Jeppe Øvlesen, Chairman of the Board, emphasized the strategic importance of the financing structure: "The Board of Directors views this financing arrangement as an important step in ensuring that Cereno Scientific (search) has the means to advance CS1 into Phase IIb and continue developing the Company's other programs toward upcoming milestones."
Market Position and Future Outlook
The financing enables Cereno to maintain momentum in business development and partnering activities while advancing its clinical programs. The company has established a new advisory relationship with investment bank Stifel (search), which served as sole and exclusive private placement agent for the financing agreement.
Cereno Scientific (search) operates from headquarters in Gothenburg, Sweden, with a US subsidiary in Boston, Massachusetts. The company trades on Nasdaq First North under the symbol CRNO B, with DNB Carnegie Investment Bank serving as Certified Adviser.
The financing addresses the company's immediate capital needs while providing a clear path to key value-inflection points across its pipeline. With FDA endorsement for CS1's Phase IIb design and positive Phase I results for CS014, Cereno is positioned to advance multiple programs simultaneously through critical development stages in the rare disease space.